PharmaShots Weekly Snapshots (September 20 – 24, 2021)

 PharmaShots Weekly Snapshots (September 20 – 24, 2021)

PharmaShots Weekly Snapshots (September 20 – 24, 2021)

Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, Approval, MDR Gram-Negative Bacterial Infections

GE Healthcare to Acquire BK Medical for ~ $1.45B

Published: Sept 24, 2021 | Tags: GE Healthcare, Acquire, BK Medical, ~ $1.45B

Roche Presents Results of Evrysdi (risdiplam) in RAINBOWFISH Study for the Treatment of Neuromuscular Disorder at WMS 2021

Published: Sept 24, 2021 | Tags: Roche, Evrysdi, risdiplam, RAINBOWFISH, Study, Neuromuscular Disorder, WMS 2021

Pfizer and BioNTech’s COVID-19 Vaccine Booster Receive the US FDA’s EUA for the Treatment of COVID-19

Published: Sept 24, 2021 | Tags: Pfizer, BioNTech, COVID-19 Vaccine Booster, US, FDA, EUA, COVID-19

Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

Published: Sept 24, 2021 | Tags: Innovent, P-II, CIBI112A201 Trial, IBI112 Plaque Psoriasis

AstraZeneca Collaborates with VaxEquity to Develop and Commercialize Self-Amplifying RNA Therapeutics

Published: Sept 24, 2021 | Tags: AstraZeneca, VaxEquity, Self-Amplifying RNA Therapeutics

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Published: Sept 23, 2021 | Tags: Immunic, University Medical Center Goettingen, IMU-838, N4-Hydroxycytidine, Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Published: Sept 23, 2021 | Tags: Gilead, Veklury, remdesivir, P-III, Trial, COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Published: Sept 23, 2021 | Tags: Incyte, Jakafi, ruxolitinib, US, FDA, Approval, Chronic Graft-Versus-Host Disease

Abbott’s Epic Plus Tissue Valves Receives the US FDA’s Approval for the Treatment of Mitral or Aortic Valve Replacement

Published: Sept 23, 2021 | Tags: Abbott, Epic Plus Tissue Valves, US, FDA, Approval, Mitral, Aortic Valve Replacement

Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Published: Sept 23, 2021 | Tags: Innovent, NMPA, sNDA, Sintilimab, Esophageal Squamous Cell Carcinoma

AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Published: Sept 23, 2021 | Tags: AbCellera, Everest, Antibody Therapies

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Published: Sept 22, 2021 | Tags: Vigeo, VT1021, P-I/II, Study, Recurrent Glioblastoma, Pancreatic Cancer

Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Published: Sept 22, 2021 | Tags: Takeda, Mirum, Maralixibat, Rare Pediatric Liver Diseases, Japan

Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory DTC at ESMO 2021

Published: Sept 22, 2021 | Tags: Exelixis, Cabometyx, cabozantinib, P-III, COSMIC-311 Trial, Radioactive Iodine-Refractory DTC, ESMO 2021

Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv) Receive the US FDA’s Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer

Published: Sept 22, 2021 | Tags: Seagen, Genmab, Tivdak, tisotumab vedotin-tftv, US, FDA, Accelerated Approval, Cervical Cancer

Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research

Published: Sept 22, 2021 | Tags: Boehringer Ingelheim, Acquire, Abexxa, Cancer Immunocology Therapies

Incyte’s Opzelura (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Atopic Dermatitis

Published: Sept 22, 2021 | Tags: Incyte, Opzelura, ruxolitinib, US, FDA, Approval, Atopic Dermatitis

Boston Scientific to Acquire Devoro for ~$336M

Published: Sept 21, 2021 | Tags: Boston, Acquire, Devoro, ~$336M

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Published: Sept 21, 2021 | Tags: Amgen, Verastem, VS-6766, Lumakras, Sotorasib, KRAS G12C-Mutant, Non-Small Cell Lung Cancer

Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases

Published: Sept 21, 2021 | Tags: Novartis, Acquire, Arctos, Optogenetics Portfolio, Gene Therapies, Eye Diseases

Bayer Signs a License and Research Agreement with Gubra to Develop Novel Peptide Therapeutics for Cardiorenal Diseases

Published: Sept 21, 2021 | Tags: Bayer, Gubra, Novel Peptide Therapeutics, Cardiorenal Diseases

Abbott’s Portico with Flexnav Tavr System Receives the US FDA’s Approval for the Treatment of Aortic Valve Disease

Published: Sept 21, 2021 | Tags: Abbott, Portico, Flexnav Tavr System, US, FDA, Approval, Aortic Valve Disease

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receives the US FDA’s Approval for the Treatment of Retinal Vascular Disorders

Published: Sept 21, 2021 | Tags: Samsung Bioepis, Biogen, Byooviz, biosimilar, ranibizumab, US, FDA, Approval, Retinal Vascular Disorders

AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small Cell Lung Cancer at ESMO 2021

Published: Sept 20, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab. P-III, CASPIAN Trial, Extensive-Stage Small Cell Lung Cancer, ESMO 2021

Exelixis’ Cabometyx (cabozantinib) Receives the US FDA’s Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer

Published: Sept 20, 2021 | Tags: Exelixis, Cabometyx, cabozantinib, US, FDA, Approval, Differentiated Thyroid Cancer

Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer

Published: Sept 20, 2021 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-826 Trial, Cervical Cancer

Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ESMO 2021

Published: Sept 20, 2021 | Tags: Regeneron, Sanofi, Libtayo, cemiplimab, P-III, EMPOWER-Lung 3 Study, Advanced NSCLC, ESMO 2021

Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021

Published: Sept 20, 2021 | Tags: Mirati, Adagrasib, MRTX849, P-I/II, KRYSTAL–1 Study, KRAS G12C-Mutated Colorectal Cancer, ESMO 2021

Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Diseases

Published: Sept 20, 2021 | Tags: Everest, Sinovent, SinoMab, XNW1011, SN1011, Renal Diseases

Related Post: PharmaShots Weekly Snapshots (September 13 -17, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post